Series A · $350M Investment Round

The Future of Food is Here

Zero Farming. Zero Hunger. 100% Complete Nutrition.
Join the revolution that's liberating humanity from the land.

View Investment Deck Explore Opportunity
$95B
Total Addressable Market
$800M
Pre-Money Valuation
10-15x
Base Case Returns
45%+
Target IRR
Investment Thesis

A Trillion-Dollar Opportunity

Three technological inflection points converging. A $95B market waiting to be disrupted. A once-in-a-generation investment window.

🌍

Global Crisis

673M

people are starving. 2.6 billion cannot eat healthily. By 2050, Earth will have 10 billion people — traditional farming is collapsing under climate change, war, and embargoes.

⚡

Technology Inflection

85%

cost reduction in precision fermentation (2015-2025). First time below traditional protein production cost. $8/kg → $1.20/kg. Scale economics now officially viable.

📈

Policy Tailwinds

$35T

in global ESG investment. China "14th Five-Year Plan" prioritizes synthetic biology. EU Farm to Fork Strategy. US USDA alternative protein subsidies. Unprecedented government support.

👥

Consumer Awakening

65%+

of Gen Z willing to try alternative protein. Post-pandemic food safety awareness fundamentally transformed. Health anxiety becomes #1 consumer driver. Organic food market CAGR 12%.

🎯

First-Mover Advantage

5-8 Years

technology lead time. 50+ patents filed. Beyond Meat and Impossible Foods proved the market — but failed on taste and completeness. We solve both with Gen 2 technology.

💰

Proven Business Model

58-71%

product gross margins. B2C premium market → B2B scale → B2G humanitarian. Revenue mix optimized for profitability first, mission second. Path to $3.5B revenue by 2037.

Market Opportunity

$95 Billion Total Addressable Market

We only need 3.7% market share to achieve $3.5B revenue. CAGR 22.8%. Five macro drivers accelerating growth.

$95B
TAM
Global Alt-Protein + Functional Foods (GFI/McKinsey 2025)
$28B
SAM
Precision Fermentation Protein + Humanitarian Nutrition (BCG 2025)
$3.5B
SOM
2037 Revenue Target (3.7% Market Share)
22.8%
CAGR
Market Growth Rate Through 2037
Competitive Advantage

Unassailable Technology Moat

50+ patents. 5-8 year technology lead. Gen 2 synthetic biology vs Gen 1 plant-based competitors.

TRL 7 Validated

Precision Fermentation

15 Patents
  • Microbial platform produces protein directly
  • Cost $1.20/kg (industry-leading)
  • 95% yield efficiency
  • 72-hour production cycle
  • Non-GMO, FDA GRAS certified
TRL 6 Validated

Cellular Agriculture

12 Patents
  • Real meat taste, zero animals
  • 92% blind test pass rate
  • Nutrition identical to real meat
  • 90% less environmental impact
  • AI taste engine (5 patents)
TRL 7 Validated

Climate Resilience

23 Patents
  • Operates -20°C to 45°C
  • 365-day year-round production
  • Unaffected by war or embargoes
  • Zero land, zero water dependency
  • Dual-site redundancy architecture
Market Position

Why Genesis Wins

Beyond Meat market cap fell from $13B to $0.8B. Impossible still needs soy. Perfect Day: single category. Genesis: Full nutrition. Complete solution.

Company
Technology
Nutritional Completeness
Beyond Meat
Plant Extraction
Low (Protein Only)
Impossible Foods
Plant + Heme
Medium (Protein + Iron)
Perfect Day
Precision Fermentation
Low (Dairy Protein Only)
Genesis Nourish
Precision Fermentation + Cellular
Full (100% Nutrition)
Revenue Trajectory

Path to $3.5B Revenue

Conservative base case. Three-scenario analysis. Even bear case delivers 5-8x returns.

2029
$50M
Revenue
2031
$500M
Revenue
2033
$1.2B
Revenue
2035
$2.0B
Revenue
2037
$3.5B
Revenue
IPO
$8B+
Valuation
10-15x
Base Case Returns for Series A Investors
$350M Series A · $800M Pre-Money · $8B+ IPO Target 2037
IRR 45%+ · Exit Window 2035-2037 · Bear Case Still 5-8x
Growth Roadmap

Execution Timeline

From foundation to IPO. Clear milestones. De-risked execution.

2026.12
Foundation
Genesis Nourish officially founded. Mission launched: End hunger with science.
2027
Series A Close
$350M raised. North Carolina R&D Center construction begins. Core team of 80 assembled.
2029
Product Launch
FDA approval secured. NC facility operational. United States & Canada market entry. First $50M revenue.
2030
Series B · Global Expansion
$300M Series B. Texas facility. Asia-Pacific markets (China, Japan, Korea). $500M annual revenue.
2032
Series C · Humanitarian Scale
$200M Series C. India, Middle East, Africa entry. WFP/UNICEF partnerships. 20M people fed. $1B+ revenue.
2037
IPO · Mission Accomplished
$8B+ IPO. 100M people fed. 3B acres farmland restored. $3.5B revenue. Net income $850M.
Leadership

World-Class Team

Harvard MBA. MIT PhD. Former FDA. Nobel Prize advisor. Goldman Sachs CFO. $5B+ portfolio experience.

CEO / Founder
Leadership Excellence
Harvard MBA · 15 Years Biotech · Former VP at Ginkgo Bioworks · Scaled $0 to $100M
CTO
Technical Innovation
MIT PhD Synthetic Biology · 20 Years Fermentation Engineering · 35 Patents · 5 Nature Publications
CFO
Financial Expertise
Wharton · 12 Years Goldman Sachs · Managed $5B+ Portfolio · 3 IPO Experiences
CSO
Scientific Authority
Stanford PhD · 12 Nature Publications · Top 5 Cellular Agriculture · FDA Advisory Committee
Advisory Board
Former FDA Deputy Commissioner
Regulatory Strategy · Accelerated Approvals · Food Safety Leadership
Advisory Board
Nobel Prize Chemistry 2018
Enzyme Engineering · Precision Fermentation Advisor · Global Recognition

Be Part of the $8 Billion Exit

Series A: $350M · Pre-Money Valuation: $800M · Post-Money: $1.15B
Preferred Stock · 2 Board Seats · Anti-Dilution Protection

Request Investment Deck Schedule Due Diligence

Investment Inquiries: invest@genesisnourish.com

Direct Line: +1 (919) 555-GENE

Target Close: Q2 2027 · Minimum Investment: $5M · Lead Investor Incentives Available